Hypothesis

Age‑related increase in intestinal epithelial mitochondrial reactive oxygen species (ROS) activates Src family kinases, which phosphorylate tight junction (TJ) proteins (occludin, ZO‑1) and trigger their caveolin‑1‑mediated internalization. This post‑translational cascade compromises barrier permeability without altering TJ gene expression, thereby linking epithelial metabolic aging to systemic inflammaging via microbial translocation.

Mechanistic Rationale

• Mitochondrial ROS rise with age due to declining antioxidant capacity and electron‑transport chain inefficiency [1].
• ROS can oxidize cysteine residues on Src kinases, promoting their autophosphorylation and activation [2].
• Active Src phosphorylates TJ proteins on tyrosine residues, a modification known to reduce membrane affinity and stimulate endocytosis [3][4].
• Caveolin‑1–dependent uptake of phosphorylated occludin/ZO‑1 has been demonstrated downstream of inflammatory cytokines [5]; we propose ROS‑Src as an upstream, cytokine‑independent trigger.
• This mechanism explains the disconnect between stable TJ mRNA levels and functional leakiness observed in aging humans and primates [6][7].

Testable Predictions

1. Elevated mitochondrial ROS in aged IECs correlates with increased TJ phosphorylation and mislocalization.
   • Measure MitoSOX fluorescence, phospho‑occludin (Tyr‑402/404) and phospho‑ZO‑1 (Tyr‑214) levels, and subcellular distribution by immunofluorescence in colonic biopsies from young (30‑45 y) vs. older (66‑89 y) donors.
2. Pharmacological suppression of mitochondrial ROS restores TJ membrane localization and reduces permeability.
   • Treat aged human colonic organoids or aged non‑human primate colonic explants with MitoQ (a mitochondria‑targeted antioxidant) for 48 h; assess phospho‑TJ levels, transepithelial resistance (TEER), and paracellular flux of FITC‑dextran.
3. Src kinase inhibition prevents age‑associated barrier leak without changing TJ gene expression.
   • Use PP2 (Src family inhibitor) or siRNA against Src in aged IECs; evaluate TJ phosphorylation, protein localization, and permeability while confirming unchanged ZO‑1, occludin, claudin‑2, JAM‑A mRNA by qRT‑PCR.
4. Mitochondrial ROS‑Src axis drives microbial translocation and systemic inflammaging markers.
   • In aged mice treated with MitoQ or Src inhibitor, quantify circulating LPS, serum zonulin, and inflammatory cytokines (IL‑6, TNF‑α) compared with vehicle controls.

Experimental Approach

• Human tissue cohort: Obtain endoscopic colonic biopsies from age‑stratified donors (n = 15 per group). Perform mitochondrial ROS imaging, phospho‑TJ immunoblotting, immunofluorescence for junctional vs. cytosolic pools, and Ussing chamber permeability assays.
• Organoid validation: Derive colonic crypts from same biopsies, culture as enteroids, apply MitoQ (500 nM) or PP2 (10 µM), and repeat ROS, TJ, and permeability readouts.
• Primate proof‑of‑concept: Treat aged rhesus macaques (n = 6) with oral MitoQ (10 mg/kg/day) for 4 weeks; collect serum zonulin, LPS, and colonic biopsies for phospho‑TJ analysis.
• Controls: Include young tissue/organoids treated with vehicle, and aged samples exposed to TNF‑α/IFN‑γ to verify cytokine‑dependent pathways remain distinct.

Falsifiability

If mitochondrial ROS scavenging or Src inhibition fails to reduce TJ phosphorylation, restore membrane localization, or lower permeability in aged human or primate preparations, the hypothesis would be refuted. Likewise, if ROS elevation does not correlate with phospho‑TJ changes across individuals, the proposed mechanistic link lacks support.

Translational Implication

Demonstrating that mitochondrial ROS‑Src signaling drives age‑related TJ dysfunction would prioritize mitochondria‑targeted antioxidants or Src inhibitors as therapeutic strategies to reinforce gut barrier integrity, curb microbial translocation, and mitigate inflammaging—interventions that can be tested in human trials without requiring gene‑expression modulation.

References

[1] https://pubmed.ncbi.nlm.nih.gov/41864519/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC6095905/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC12862612/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC8912763/ [5] https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2024.1380713/full [6] https://journals.biologists.com/dmm/article/16/4/dmm049969/308869/Intestinal-barrier-dysfunction-an-evolutionarily [7] https://pubs.rsc.org/en/content/articlelanding/2026/fo/d5fo03583j